Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors: Featuring 174 Companies
DUBLIN, Apr. 09, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/cqkvzx/competitor) has announced the addition of the "Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors" report to their offering.
This Competitive Intelligence Report about Therapeutic Antibodies 2015: Biosimilars & Biosuperiors provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of April 2015.
Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached US$ 82.2 bln (+8.6% vs previous year) in the year 2014.
The report lists specifically for each target the branded products with their 2014 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.
The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets:
- VEGF
- TNF
- Her2
- CD20
- EGF-R
- B7.1/B7.2 (CD80/CD86)
- IL-6R
- Alpha4/beta1/7 integrin
- IgE
- RSV
- RANKL
- Complement C5
- IL-12/IL-23
- CD52
Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Company
- Product Category
- Indication
- R&D Stage and additional comments with a hyperlink leading to the source of information
Key Topics Covered:
1) 2014 Sales of Therapeutic Antibodies
2) VEGF Antibodies
3) TNF Antibodies
4) Her2 Antibodies
5) CD20 Antibodies
6) EGF-R Antibodies
7) RANKL Antibodies
8) Complement C5 Antibodies
9) Interleukin-12/-23 Antibodies
10) Alpha4/Beta1/7 Antibodies
11) IgE Antibodies
12) CD80/86 (B7-1/B7-2) Antibodies
13) Interleukin-6 Receptor (IL-6R) Antibodies
14) Respiratory Syncytial Virus (RSV) Antibodies
15) CD52 Antibodies
Companies Mentioned: 30 of the 174 Companies Featured
- 3SBio
- AbbVie
- Ablynx
- Actavis
- ActoGenix
- ADC Therapeutics
- AET Biotech
- Celgene
- Celltrion
- Ceres Oncology
- CIMAB
- Clearside Biomedical
- Eisai
- Eli Lilly
- Emergent BioSolutions
- Epirus Biopharmaceuticals
- Harvest Moon Pharmaceuticals
- Hospira
- Humabs Biomed
- Merck Serono
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Merus
- Reliance Life Sciences
- Roche
- R-Pharm
- RuiYi
- Samsung Bioepis (JV of Samsung and Biogen Idec)
- Sanofi
- Shanghai BioMabs Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/cqkvzx/competitor
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article